FOR THE MEMBERSHIP LIST OF THE ADNI STEERING COMMITTEE
FOR A LIST OF ALL ADNI INVESTIGATORS FOLLOW THIS LINK
 Michael W. Weiner, M.D. (UCSF, NCIRE, VA) -
Principal Investigator
Michael W. Weiner M.D. is the Director of the Magnetic Resonance Unit at the VA Medical Center in San Francisco, and Professor of Radiology, Medicine, Psychiatry and Neurology at UC San Francisco. He was one of the first scientists to obtain MRS spectra from an intact animal, and has published over 310 peer reviewed journal publications, of which 250 have been clinical MRI/MRS studies.
 Paul Aisen, M.D. (University of California, San Diego) - PI Clinicial Core
Paul Aisen is Professor of Neurosciences at the University of California, San Diego School of Medicine and Director of the Alzheimer's Diseases Cooperative study(ADCS). The ADCS has completed several clinical trials with major public health impact including studies of high dose vitamin E, studying the effects of estrogens on AD progression and examining the ability of Vitamin E and Aricept to prevent progression from MCI to AD.
 Ronald Petersen MD, PhD (Mayo Clinic) - Co-PI Clinical Core
Ronald Petersen
is the Director of the ADC at Mayo Clinic and Professor of Neurology. He has carried out extensive studies in subjects transitioning from Normal to AD
and has developed the concept of mild cognitive impairment(MCI).
 Clifford Jack, M.D. (Mayo Clinic, Rochester, Minnesota) - PI of MRI component of Neuroimaging Core
Clifford Jack MD is the most prominent neuroradiologist in the AD field. His major contribution has been to describe the changes in the volume of the hippocampus in AD and MCI compared to elderly controls, to describe the rates of change in these populations, and to correlate these changes with cognition and transitions to MCI and to AD.
 William Jagust, M.D. (University of California, Berkeley) - PI of PET component of Neuroimaging Core
William Jagust, MD has been involved in neuroimaging of AD for many years. He first quantified hippocampal volume in AD with MRI patients, was one of the first to demonstrate temporoparietal hypoperfusion with SPECT 48, and longitudinal changes of FDG PET in AD. He reported relationships between SPECT perfusion and pathological findings on autopsy, and that SPECT provides information predictive of pathological diagnosis above that obtained with clinical examination.
 John Q. Trojanowski, M.D., Ph.D. (University of Pennsylvania) - PI of Biomarkers component of Clinical Core
Dr. Trojanowski's research focuses on the role of protein misfolding in
neurodegeneration, which is a core disease mechanism shared by Alzheimer's (AD), Parkinson's (PD) and related disorders. Since early diagnosis of AD is critical to developing effective AD therapies, Dr. Trojanowski exploits insights into disease mechanisms to develop and validate relevant and informative AD biomarkers.
 Arthur w. Toga, Ph.D. (University of California, Los Angeles) - PI of Infomatics Core
Arthur Toga, PhD is a professor of Neurology at UCLA, founder and Director of the Laboratory of Neuro Imaging (LONI), Co-Director of the UCLA Brain Mapping Center and the founding editor of the journal, NeuroImage. He is a member of the UCLA Brain Research Institute and past Director of Admissions of the Neuroscience Graduate Program. Dr. Toga has a career-long funding and publication record in the analysis, registration and modeling of structural and functional images obtained from many species, including humans.
 Laurel Beckett, PhD. (University of California, Davis) - PI of Statistics Core
Laurel Beckett, Ph.D., has been involved in AD research for many years.
She was the biostatistician for the East Boston AD studies that first
estimated the population prevalence and incidence of AD and projected
those numbers to the US population. Her methodological research in
longitudinal studies and population based studies has helped to
describe patterns and correlates of clinical decline both in AD and in
the general population.
|
